Loss of β-Catenin Induces Multifocal Periosteal Chondroma-Like Masses in Mice  by Cantley, Leslie et al.
The American Journal of Pathology, Vol. 182, No. 3, March 2013ajp.amjpathol.orgMUSCULOSKELETAL PATHOLOGY
Loss of b-Catenin Induces Multifocal Periosteal
Chondroma-Like Masses in Mice
Leslie Cantley,* Cheri Saunders,* Marta Guttenberg,y Maria Elena Candela,* Yoichi Ohta,* Rika Yasuhara,z Naoki Kondo,z
Federica Sgariglia,* Shuji Asai,* Xianrong Zhang,x Ling Qin,x Jacqueline T. Hecht,{ Di Chen,k Masato Yamamoto,**
Satoru Toyosawa,yy John P. Dormans,xzz Jeffrey D. Esko,xx Yu Yamaguchi,{{ Masahiro Iwamoto,*x Maurizio Paciﬁci,*x and
Motomi Enomoto-Iwamoto*xFrom the Translational Research Program in Pediatric Orthopaedics,* the Department of Pathology and Laboratory Medicine,y and Division of Orthopedic
Surgery,zz Department of Surgery, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania; the Department of Orthopaedic Surgery,z Thomas
Jefferson University, Philadelphia, Pennsylvania; the Department of Orthopedic Surgery,x School of Medicine, University of Pennsylvania, Pennsylvania; the
Division of Medical Genetics,{ Department of Pediatrics, The University of Texas Medical School at Houston, Houston, Texas; the Department of
Biochemistry,k Rush University, Chicago, Illinois; the Department of Surgery,** University of Minnesota, Minneapolis, Minnesota; the Department of Oral
Pathology,yy Graduate School of Dentistry Osaka University, Suita, Japan; the Department of Cellular and Molecular Medicine,xx University of California San
Diego, La Jolla, California; and the Sanford Children’s Health Research Center,{{ Sanford-Burnham Medical Research Institute, La Jolla, CaliforniaAccepted for publicationC
P
hNovember 7, 2012.
Address correspondence to
Motomi Enomoto-Iwamoto,
D.D.S., Ph.D., Translational
Research Program in Pediatric
Orthopaedics, Division of
Orthopedic Surgery,
Department of Surgery,
Children’s Hospital of
Philadelphia, 3615 Civic Center
Blvd., ARC902, Philadelphia,
PA 19104. E-mail:
iwamotom1@email.chop.edu.opyright ª 2013 American Society for Inve
ublished by Elsevier Inc. All rights reserved
ttp://dx.doi.org/10.1016/j.ajpath.2012.11.012Osteochondromas and enchondromas are the most common tumors affecting the skeleton. Osteochon-
dromas can occur as multiple lesions, such as those in patients with hereditary multiple exostoses.
Unexpectedly, while studying the role of b-catenin in cartilage development, we found that its conditional
deletion induces ectopic chondroma-like cartilage formation in mice. Postnatal ablation of b-catenin in
cartilage induced lateral outgrowth of the growth plate within 2 weeks after ablation. The chondroma-like
masses were present in the ﬂanking periosteum by 5 weeks and persisted for more than 6 months after
b-catenin ablation. These long-lasting ectopicmasses rarely contained apoptotic cells. In good correlation,
transplants ofb-catenin-deﬁcient chondrocytes into athymicmice persisted for a longer period of time and
resisted replacement by bone compared to control wild-type chondrocytes. In contrast, a b-catenin
signaling stimulator increased cell death in control chondrocytes. Immunohistochemical analysis revealed
that the amount of detectable b-catenin in cartilage cells of osteochondromas obtained from hereditary
multiple exostoses patients was much lower than that in hypertrophic chondrocytes in normal human
growth plates. The ﬁndings in our study indicate that loss of b-catenin expression in chondrocytes induces
periosteal chondroma-like masses and may be linked to, and cause, the persistence of cartilage caps in
osteochondromas. (Am J Pathol 2013, 182: 917e927; http://dx.doi.org/10.1016/j.ajpath.2012.11.012)Supported by NIH grants AR058382 (M.P.), AR061758 (M.P.),
AR062908 (M.P.), GM33063 (J.E.), and a Foerderer Award (FY2012) from
the Children’s Hospital of Philadelphia (M.E.-I.).
A guest editor acted as editor-in-chief for this manuscript. No person at
Thomas Jefferson University was involved in the ﬁnal disposition of this
article.Osteochondromas and enchondromas are the most com-
mon tumors affecting the skeleton.1,2 Osteochondromas are
cartilage-covered masses that form near the growth plate and
bone surface, whereas enchondromas form within the growth
plate and bone marrow. Both types of benign tumors can
cause mechanical impairment of movement and also pain due
to impingement or compression of nerves and blood vessels,
particularly when they are present at multiple sites.3,4 These
benign tumors may become malignant.5e7 The potential for
malignant progression is greater in patients with syndromes,
such as Ollier disease, Maffucci syndrome, or hereditary
multiple exostoses (HME), the latter also known as multiple
osteochondroma.5e7 Current treatments largely rely onstigative Pathology.
.surgical excision.3,8 Both benign and malignant cartilage
tumors are generally resistant to chemotherapy and radio-
therapy.5,9 Thus, a better understanding of the cellular and
molecular mechanisms underlying cartilage tumor formation
and growth is critical for the development of new therapeutic
strategies and treatments.
Cantley et alRecent studies have indicated that several genes play
important roles in cartilage tumor formation.4,5 Hopyan
et al10 found mutations in parathyroid hormone receptor
1 (PTHR1) in patients with multiple enchondromas. These
authors generated mice harboring the same PTHR1mutations
that displayed a similar enchondroma formation. In addition,
they found that the PTHR1 mutations caused constitutive
activation of hedgehog signaling in cultured chondrocytes
and that overexpression of Gli2, a downstream molecule of
hedgehog signaling, induced enchondromas in mice.10 In the
follow-up studies, however, it was found that certain cohorts
of enchondromatosis patients do not have PTHR1 muta-
tions11 and that enchondroma formation may actually be
independent of hedgehog signaling.12 Thus, the pathogenesis
of enchondroma formation remains to be clariﬁed.
Mutations in EXT1 and EXT2 genes have been associ-
ated with hereditary multiple exostoses (HME) (multiple
osteochondroma).5e7 Mutations in these genes are often mis-
sense or frame shift and cause synthesis of lower levels of (and
shorter) heparan sulfate chains.4,5 This is because EXT1 and
EXT2 encodeGolgi-associated enzymes are responsible for the
polymerization of the chains.13 Insufﬁciency of heparan
sulfate-rich proteoglycans is thought to be a cause of osteo-
chondroma formation.4,5,13 Heparan sulfate proteoglycans are
important for the regulation of many signaling pathways that
include hedgehog, bone morphogenetic protein, ﬁbroblast
growth factor, and Wnt pathways.13,14 All of these pathways
are critical regulators for chondrogenic differentiation and
chondrocyte differentiation.15,16 It is likely that dysregulation
of these signaling pathways resulting from heparan sulfate
deﬁciency may trigger abnormal behavior of growth plate
chondrocytes or induce ectopic chondrogenic differentiation,
leading to ectopic cartilage formation. Recently, several Ext
mutant mouse lines have been established.17e19 All of these
transgenic mouse lines show multifocal ectopic cartilaginous
masses with microscopical and structural similarities to
osteochondromas found in HME patients.17e19 The cellu-
lar and molecular mechanisms underlying EXT mutation-
associated chondroma formation, however, remains largely
unclear.
The Wnt/b-catenin signaling pathway is essential for
regulation of normal cartilage development, maintenance of
permanent cartilage, and growth plate function.20e24
Previous reports have shown that inactivation of this
signaling pathway impairs cartilage and skeletal develop-
ment. Conditional ablation of the b-catenin gene in limb
skeletogenic cells induces a delay in endochondral bone
formation and the formation of abnormal cartilaginous
masses during embryonic development.25e27 In addition,
overexpression of a Wnt antagonist strongly inhibits both
hypertrophy of chondrocytes and progression of endochon-
dral ossiﬁcation.28 Recently, we generated compound trans-
genic mice in which we induced postnatal conditional
ablation of b-catenin in cartilage.24 We found that the
resulting b-catenin deﬁciency impaired growth plate function
and skeletal growth. In addition, the mice developed ectopic918cartilaginous masses located near the bone surface but not
within the bone marrow. In the present study, we character-
ized the pathohistology of these ectopic cartilaginous masses
and investigated their possible cell origin and fate, and also
related the ﬁndings to human osteochondromas.
Materials and Methods
Transgenic Mice
All mouse studies were conducted with approval by the
Institutional Animal Care and Use Committee. b-cateninﬂ/ﬂ;
Rosa-LacZ mice that harbors ﬂoxed b-catenin (homo)
and Cre-inducible LacZ (homo) were generated by mating
b-catenin ﬂoxed mice (b-cateninﬂ/ﬂ) possessing LoxP sites in
introns 1 and 6 in the b-catenin gene (6.129-Ctnnb1tmKem/
KnwJ line purchased from the Jackson Laboratory, Bar Harbor,
ME) with R26Rosa-lox-stop-lox-LacZ (Rosa-LacZ ) mice
(129S-Gt(ROSA)26Sortm1Sor/J from the Jackson Laboratory).
Col2CreERb-cateninﬂ/ﬂ mice were generated by mating
b-cateninﬂ/ﬂ mice with Col2CreER mice that harbor Cre re-
combinase,which is linked to amodiﬁed estrogen ligand binding
domain under the control of collagen 2a1 promoter sequences.
Two independent Col2CreER mouse lines, herein referred to as
Col2CreER29 andCol2CreER (D.C.)30wereoriginallygenerated
by Drs. Susan Mackem (National Cancer Institute, Frederick,
MD) and Di Chen (Rush University, Chicago, IL) respectively.
The Col2CreER;b-cateninﬂ/ﬂ mice were mated with the
b-cateninﬂ/ﬂ;Rosa-LacZ or b-cateninﬂ/ﬂ mice, and the resulting
littermates received i.p. injectionsof tamoxifen (100mg/10mLper
mouse) at day 5, 6 and 7 or day 5 and 7 after birth. Themicewere
sacriﬁced at 1, 2, 5, and 8weeks, or 6months after completion of
the tamoxifen injections. The total number of mice inspected in
b-cateninﬂ/ﬂ with or without Rosa-LacZþ/ and Col2CreER;
b-cateninﬂ/ﬂ with or without Rosa-LacZþ/ was two mice for
1week, four for 2weeks, eight for 5weeks, four for 8weeks, and
three for 6 months post-tamoxifen injections.
CagCreER;b-cateninﬂ/ﬂ mice were generated by mating
b-cateninﬂ/ﬂmicewithCagCreERmice that harbor a tamoxifen-
inducible Cre (CreER) driven by the chick b-actin promoter/
enhancer coupled to the cytomegarovirus immediate-early
enhancer STOCK Tg(CAG-cre/Esr1*)5Amc/J from the Jack-
son Laboratory. Col2CreER;Ext1þ/ mice were generated by
mating Ext1þ/ mice17 and then mated with Ext1 ﬂoxed (Ext1ﬂ/
ﬂ) mice,31 and the resulting littermates,Col2CreER; Ext1ﬂ/ and
Ext1ﬂ/ received i.p. injections of tamoxifen (100 mg/10 mL per
mouse) at day 5 and 7 after birth.Col2CreER;Ext1ﬂ/ﬂmice were
also generated and received 100 mg/10 mL i.p. injections of
tamoxifen per mouse at day 5 after birth. The mice were sacri-
ﬁced 2 weeks after completion of the tamoxifen injections.
Histological, Histochemical, and
Immunohistochemical Analyses
Knee joints were dissected, ﬁxed with 4% (v/v) para-
formaldehyde, decalciﬁed with EDTA for 7 to 10 days, andajp.amjpathol.org - The American Journal of Pathology
Loss of b-Catenin and Chondroma Formationembedded in parafﬁn. Longitudinal sections of tibias and
femurs (6 mm) were prepared and subjected to histological
staining with H&E and safranin O and fast green. The
sections were subjected to b-galactosidase (LacZ) activity
staining using X-Gal Stock and Stain Base Solution (EMD
Millipore Corporation, Billerica, MA), according to the
manufacturer’s protocol, and then counterstained with eosin.
Proliferating activity was examined by detection of prolif-
erating cell nuclear antigen (PCNA) using a PCNA staining
kit (Life Technologies, Grand Island, NY) followed by
counterstaining with methyl green. The PCNA staining
results were observed under a Nikon Eclipse TE400 mic-
roscope (Nikon Instruments Inc., Melville, NY). SPOT
Advanced software version 5.0 (Diagnostic Instruments
Inc., Sterling Heights, MI) was used to capture and analyze
images. The number of PCNA-positive cells and number of
nuclei in three lateral and center regions of the growth plate
were analyzed in two b-cateninﬂ/ﬂ and two Col2CreER;b-
cateninﬂ/ﬂ mice. The ratio of the PCNA-positive cell number
to the total cell number was calculated. Localization of
collagen 10 was detected by immunohistochemical staining
with an anti-collagen 10 antibody. Sections were treated
with 0.1% pepsin in 0.02 N HCl for 10 minutes at 37C,
incubated with anti-collagen 10 antibody rabbit serum
(1:1000; Cosmo Bio, Tokyo, Japan) in 10% goat serum in
PBS for 1 hour at room temperature, followed by visuali-
zation of the antibody using the SuperPicture Polymer
detection kit (Life Technologies) and counterstaining with
methyl green. The sections that had been stained with
nonimmune rabbit IgG (5 mg/mL; Vector Laboratories,
Burlingame, CA) did not show speciﬁc staining.
To evaluate localization of osteoclasts, tartrate-resistant
acid phosphatase (TRAP) staining was performed using
a TRAP staining kit (Sigma-Aldrich, St. Louis, MO) by
following the manufacturer’s protocol.Figure 1 Structural deformity and ectopic cartilage formation in long bones an
(AeD) and their littermate Col2CreER;b-cateninﬂ/ﬂ mice (EeH) received 100 mg/10
5 weeks after completion of tamoxifen injections. Skeletal deformity and ectopic c
examined by radiographical inspection (A, B, E, and F) and alcian blue/alizarin
formation. Circles indicate regions of interest for ectopic cartilage formation in
The American Journal of Pathology - ajp.amjpathol.orgThe mouse growth plate parafﬁn sections were incubated
with the rabbit polyclonal antieb-catenin antibody (1:250;
Cell Signaling Technology, Inc., Danvers, MA), followed
by incubation with horseradish peroxidase conjugated anti-
rabbit antibody (1:100; Vector Laboratories) and ImmPACT
SG peroxidase substrate (Vector Laboratories) with methyl
green counter staining.
Skeletal Analysis
Limb skeletons were analyzed by taking soft X-ray images
using Bioptics piXarray100 (Core Medical Imaging, Inc.,
Kenmore, WA) using the automatic exposure mode. The knee
joints and ribs were stained with alcian blue and alizarin red.
Chondrocyte Cultures
Chondrocytes were isolated from the epiphyseal cartilage
from B6129SF2/J mice (Jackson Laboratory) at day 3 to 5
after birth. The epiphyseal cartilage pieces were digested
with 0.05% trypsin in HBSS for 1 hour at 37C and were
then incubated with 86 U/mL collagenase type I (Wor-
thington Biochemical Corporation, Lakewood, NJ) in
serum-free Dulbecco’s modiﬁed Eagle’s medium overnight.
The dissociated cells were plated on collagen 1 coated wells
at the density of 30,000 cells per well in 96-well plates or
50,000 cells per well in 4-well culture slides (BD Biosci-
ences, San Jose, CA) and cultured in Dulbecco’s modiﬁed
Eagle’s medium containing 10% fetal bovine serum
(Gemini Bio-Products, West Sacramento, CA). The cultures
were incubated with 6BIO or Me-7BIO (Santa Cruz Bio-
technology, Inc., Santa Cruz, CA) in the presence or
absence of 3 mmol/L CaCl2 and 6 mmol/L NaH2PO4 for
24 to 48 hours and subjected to a cell viability assay
or terminal deoxynucleotidyl transferase-mediated dUTPd ribs in tamoxifen-injected Col2CreER;b-cateninﬂ/ﬂ mice. b-cateninﬂ/ﬂ mice
mL i.p. injections of tamoxifen per mouse at P5 to P7. Mice were sacriﬁced
artilage formation in knee joints (A, B, DeF, and H) and ribs (C and G) were
red skeletal staining (C, D, G, and H). Arrows indicate ectopic cartilage
the knees.
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Figure 2 Outgrowth of growth plate and ectopic cartilage in perios-
teum in tamoxifen-injected Col2CreER;b-cateninﬂ/ﬂ mice. Col2CreER;
b-cateninﬂ/ﬂ mice (CeJ) and their littermate b-cateninﬂ/ﬂ mice (A and B)
received 100 mg/10 mL i.p. injections of tamoxifen per mouse at P5 to P7.
Longitudinal sections of knee joints were prepared at 2 weeks (A, C, E, G,
and I) or 5 weeks (B, D, F, H, and J) after completion of the tamoxifen
injections. Arrows indicate out-growing growth plate (C) or ectopic
cartilage masses embedded in the periosteum (D, H, and J). Boxed areas in
C and D are enlarged in E and F, respectively.
Cantley et alnick-end labeling (TUNEL) assay. To examine cell
viability, the cultures were incubated with 120 mg/mL 3-
(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium
bromide (MTT, Life Technologies) in PBS for 1 hour at
37C and then solubilized with 0.04N HCl in isopropanol.
The absorbance was measured at 595 nm. The MTT (Life
Technologies) substrate is converted to purple formazan by
mitochondrial reductase. The conversion rate is used as
a measure of viable cells. The cultures were also ﬁxed with
3.7% neutralized formalin and subjected to a TUNEL
assay using the ApopTag red in situ apoptosis detection kit
(EMD Millipore Corporation) followed by DAPI nuclear
staining.
Epiphyseal chondrocytes were also isolated from Cag-
CreER;b-cateninﬂ/ﬂ mice and the control b-cateninﬂ/ﬂ
littermates at days 3e5 after birth. The cultures were treated
with 1 mmol/L 4-hydroxytamoxifen (Sigma-Aldrich) for 48
hours, followed by incubation without 4-hydroxytamoxifen
for the additional 48 hours, harvested, and mixed with
a collagen solution (3 mg/mL Cellmatrix; Nitta Gelatin Inc.,
Osaka, Japan) at the concentration of 6.0 to 8.0  106/mL
by following the manufacturer’s protocol. There was 250
mL per mouse cell mixture that was subcutaneously injected
into athymic mice (CD-1 Nude Mouse; Charles River
Laboratories International, Inc., Wilmington, MA). Trans-
plants were collected 4 weeks later and subjected to histo-
logical inspection. The parallel cultures were harvested and
subjected to immunoblot analysis to detect b-catenin and
ERK using the antieb-catenin antibody (1 mg/mL; BD
Biosciences) and the anti-ERK antibody (1:1000; Cell
Signaling Technology, Inc.).
To remove heparan sulfate proteoglycan, the chon-
drocytes isolated from B6129SF2/J mice were pre-treated
with heparinase I from Flavobacterium heparium (Sigma-
Aldrich) at 10 unit/mL for 16 hours and subjected to Top-
ﬂash reporter analysis32 using a dual reporter kit (Promega,
Madison WI).
Human Tissues
Parafﬁn sections of osteochondromas surgically removed
from consenting HME patients, as well as rib cartilage
removed during autopsy, were provided by the Pathology
Core of the Children’s Hospital of Philadelphia. The slides
we used in this study had been made for clinical diagnosis,
but were no longer needed and were completely de-
identiﬁed before being provided for the present study. The
study was determined to be nonhuman subjects’ research by
The Children’s Hospital of Philadephia Research Institute’s
Institutional Review Board.
The sections were treated with 0.1% pepsin in 0.02 N HCl
for 10 minutes at 37C after deparafﬁnization, blocked with
10% goat serum in PBS for 1 hour, and incubated with the
antieb-catenin mouse antibody (1 mg/mL, BD Biosciences)
or nonimmune mouse IgG (1 mg/mL, Vector Laboratories) at
4C overnight. The sections were then incubated with Alexa920Fluor 594-labeled anti-mouse IgG (1 mg/mL) for 1 hour at
room temperature followed by DAPI staining for nuclei. The
images were taken with a Nikon Eclipse TE2000-U ﬂuores-
cent microscope (Nikon Instruments Inc.). ImagePro software
version 5.0 (Media Cybermetics, Inc., Rockville, MD) was
used to capture and analyze images of 5 to 7 ﬁelds per sample
(seven osteochondromas and four rib cartilages). The b-cat-
enin images were ﬁrst processed by subtraction of the
background staining intensity that had been obtained from the
samples stained with the nonimmune IgG. The number of b-
catenin positive cells and DAPI-positive cells were counted,
and the ratio of the b-catenin positive cell number to the
DAPI-positive cell number was calculated.ajp.amjpathol.org - The American Journal of Pathology
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Results were analyzed using InStat 3 version 3.1a (Graph-
Pad Software, Inc., La Jolla, CA). A one-way analysis of
variance with a Tukey-Kramer Multiple Comparison Test
was used to identify the differences. The threshold for
signiﬁcance for all tests was set as P < 0.05.
Results
Formation of Multiple Ectopic Cartilaginous Masses in
Tamoxifen-Treated Col2CreER;b-cateninﬂ/ﬂ Mice
Col2CreER;b-cateninﬂ/ﬂ and control b-cateninﬂ/ﬂ mice re-
ceived tamoxifen injection at days 5, 6 and 7 or days 5 and 7
after birth to conditionally ablate the b-catenin gene and were
kept until 5 weeks after completion of tamoxifen injections.
X-ray analysis revealed that the femur and tibia of tamoxifen-
injected Col2CreER;b-cateninﬂ/ﬂ mice had become severely
deformed (Figure 1, E and F), whereas, the corresponding
skeletal elements in control tamoxifen-injected b-cateninﬂ/ﬂ
mice showed no obvious abnormality (Figure 1, A and B).
The knee joints and ribs were harvested and stained with
alcian blue and alizarin red to inspect skeletal deformity and
possible formation of ectopic cartilage. The costochondral
junctions of ribs in the tamoxifen-injected Col2CreER;
b-cateninﬂ/ﬂ mice were swollen (Figure 1G) and displayed
ectopic cartilaginous masses that were positive for alcian blue
staining (Figure 1G). In contrast, ribs in the tamoxifen-
injected control mice were normal (Figure 1C). Ectopic
cartilaginous masses were also detected in tibias and femurs
of the tamoxifen-injected Col2CreER;b-cateninﬂ/ﬂ mice
(Figure 1H), but not in the controls (Figure 1D). SimilarFigure 3 Localization of Cre-positive cells after tamoxifen injection in Col2Cre
B, and DeF) and littermate b-cateninﬂ/ﬂ;Rosa-LacZ mice (C) received 100 mg/10 m
of knee joints were prepared at 1 (AeC), 2 (D and E), or 8 (F) weeks after comple
B and E: Magniﬁed images of the boxed areas in A and D, respectively.
The American Journal of Pathology - ajp.amjpathol.orgoutcomes were seen using the other Col2CreER (DC) mouse
line. The Col2CreER;b-cateninﬂ/ﬂ mice that had not received
a tamoxifen injection did not show any signiﬁcant skeletal
abnormality (data not shown).
To examine the histology of ectopic cartilaginous masses,
we prepared longitudinal sections of knee joints that had
been harvested from the tamoxifen-injected Col2CreER;
b-cateninﬂ/ﬂ or the control b-cateninﬂ/ﬂ mice at 2 (Figure 2,
A, C, E, G, and I) or 5 weeks (Figure 2, B, D, F, H, and J)
after completion of the tamoxifen injections. The ectopic
masses were present along the lateral side of the tibia and
femur growth plates in the direction of the metaphysis in the
injected Col2CreER;b-cateninﬂ/ﬂ mice at 2 weeks after the
tamoxifen injections (Figure 2C), and were present in both
the distal femur and proximal tibia (Figure 2, C, E, and G).
Growth plates of the control b-cateninﬂ/ﬂ mice were normal
(Figure 2A). Five weeks after the tamoxifen injections, the
ectopic cartilaginous masses were embedded in the perios-
teum (Figure 2, D, F, H, and J). They retained a columnar
structure, but did not contain typical hypertrophic cells
(Figure 2F). Both mutant femur and tibia showed de-
creased bone volume (Figure 2D) compared to the controls
(Figure 2B), as previously reported.24 Some ectopic carti-
laginous masses were disconnected from the growth plate
(Figure 2J). Interestingly, the ectopic masses showed simi-
larities to those in the Ext mutant mice, which have been
reported as osteochondroma animal models.17e19 Indeed,
we conﬁrmed that conditional Ext1 ablation caused forma-
tion of similar outgrowths near the growth plates at early
time points after gene ablation was induced (Supplemental
Figure S1). In addition, b-catenin immunostaining re-
vealed that the growth plate of Col2CreER;Ext1ﬂ/ﬂ mice
injected with tamoxifen at P5 (100 mg/10 mL per mouse)ER;b-cateninﬂ/ﬂ;Rosa-LacZ mice. Col2CreER;b-cateninﬂ/ﬂ;Rosa-LacZ mice (A,
L i.p. injections of tamoxifen per mouse at P5 and P7. Longitudinal sections
tion of the tamoxifen injections and subjected to b-galactosidase staining.
921
Figure 4 Imbalance of cell proliferating activity in growth plate in the
tamoxifen injected Col2CreER;b-cateninﬂ/ﬂmice. Col2CreER;b-cateninﬂ/ﬂ;Rosa-
LacZ mice (A and B) and littermate b-cateninﬂ/ﬂ;Rosa-LacZ mice (C and D)
received 100 mg/10 mL i.p. injections of tamoxifen per mouse at P5 and P7.
Longitudinal sections of knee joints were prepared at 2 weeks after completion
of the tamoxifen injections and subjected to PCNA staining. E: Ratios of PCNA-
positive cells were measured (see Materials and Methods). *P < 0.05
Cantley et alshowed much weaker staining, especially in the hypertro-
phic zone (Supplemental Figure S1F), suggesting that
Ext1-deﬁcient chondrocytes had weaker b-catenin signal-
ing activity. In good agreement, heparinase-treated chon-
drocytes in culture displayed reduced responsiveness to
Wnt3a treatment compared to control cells (Supplemental
Figure S1G).Figure 5 PCNA, collagen 10, TUNEL, and TRAP staining in ectopic
cartilaginous masses at early and late stages after tamoxifen injections.
Col2CreER;b-cateninﬂ/ﬂ;Rosa-LacZ mice received 100 mg/10 mL i.p. injec-
tions of tamoxifen per mouse at P5 and P7. Longitudinal sections of knee
joints were prepared at 2 weeks (A, C, E, G, and I) or 8 weeks (B, D, F, H,
and J) after completion of the tamoxifen injections and subjected to PCNA
(A and B), collagen 10 immunostaining (C and D), TUNEL (E and F), and
TRAP (I and J) staining. The arrows in E indicates apoptotic cells. G and H:
Phase contrast images (E and F), respectively.Characterization of b-Catenin-Deﬁcient Chondrocytes
Next, we generated Col2CreER;b-cateninﬂ/ﬂ mice in
R26Rosa-lox-stop-lox-LacZ background and examined where
the Cre activity was induced and how the Cre-sensitive cells
contributed to ectopic cartilage formation by monitoring
Cre-induced LacZ activity. One week after completion of the
tamoxifen injections, a large number of LacZ positive cells
were present in the entire cartilage, but hardly any were
present in the perichondrium and periosteum (Figure 3,
A and B), indicating that the induction of Cre activity is
largely limited to cartilage. The control tamoxifen-injected
b-cateninﬂ/ﬂ;Rosa-LacZþ/ mice essentially displayed no
LacZ-positive cells (Figure 3C). The ectopic cartilaginous922masses present at 2 weeks after the tamoxifen injections were
composed of both LacZ-positive and negative cells, and the
hypertrophic cells in the outgrowing lesions were mostly
negative (Figure 3, D and E). Eight weeks after the last
tamoxifen injection, the ectopic cartilage masses did not
contain enlarged hypertrophic cells and were largely
composed of LacZ-positive cells (Figure 3F). These ﬁndings
suggest that the b-catenin-deﬁcient cells autonomously form
the ectopic cartilage masses and could originate from the
growth plate.
PCNA staining was performed to examine cell prolifer-
ating activity. The PCNA-positive cells were evenly locatedajp.amjpathol.org - The American Journal of Pathology
Loss of b-Catenin and Chondroma Formationalong the edge and center of the growth plate in the
tamoxifen-injected control mice (Figure 4, A and B). In
contrast, PCNA-positive cells were abnormally distributed
in the growth plate in tamoxifen-injected Col2CreER;
b-cateninﬂ/ﬂ mice. The number of labeled cells was lower in
the center (Figure 4D) as compared with the outgrowing
lesion (Figure 4C). A semiquantitative analysis supported
this observation (Figure 4E), indicating that the chon-
drocytes in the center of the growth plate in b-catenin
deﬁcient mice exhibited lower proliferating activity that
those in the outgrowths.
Then we compared the ectopic cartilaginous masses at the
initial and later stages. The outgrowing masses at 2 weeks
after the tamoxifen injections showed phenotypic charac-
teristics similar to those of the normal growth plates,
including collagen 10 expression in the hypertrophic zone
(Figure 5C), presence of apoptotic cells (Figure 5, E and G),
and TRAP-positive osteoclasts (Figure 5I) under the hy-
pertrophic zone. There were no signiﬁcant changes in
expression levels of collagen 10 and the number of ap-
optotic cells and TRAP-positive cells in control versus
b-catenin-deﬁcient growth plates, although the latter were
structurally overgrowing. At the later stages, the majority of
cells in the ectopic masses were still positive for PCNA
(Figure 5B). Collagen 10-producing cells (Figure 5D) and
apoptotic cells were not found (Figure 5, F and H), although
TRAP-positive cells were detected adjacent to the ectopic
cartilage (Figure 5J). These ﬁndings indicate that the ectopic
chondrocytes retained their proliferating activity and did not
undergo hypertrophy and apoptosis.
The ectopic cartilaginous masses were still present at
6 months after the tamoxifen injections. The cartilaginous
masses gradually increased in volume, bulging into adjacentFigure 6 Resistance of
Epiphyseal chondrocytes w
(B and C) cultured until su
2 days followed by culturin
harvested and subcutaneo
resulting ectopic masses w
histological inspection. C:
conﬁrmed that the CagCreER
b-cateninﬂ/ﬂ cells containe
The American Journal of Pathology - ajp.amjpathol.orgskeletal muscles (Supplemental Figure S2A). Microscopy of
these lesions showed proliferating chondrocytes, cytological
atypia, including bi-nucleated cells (arrows), and prominent
vascularity reminiscent of capillary ingrowth (Supplemental
Figure S2B). Disorganization of tissues and the appearance
of atypical cells in the cartilaginous masses were observed
in each of three separate samples (Supplemental Figure S2,
BeD).
The previously described data indicated that loss of
b-catenin rendered chondrocytes more resistant to bone
replacement in the process of endochondral ossiﬁcation. To
test this possibility more directly, we isolated chondrocytes
from the compound mice (CagCreER;b-cateninﬂ/ﬂ) har-
boring ﬂoxed b-catenin and a tamoxifen-inducible Cre
(CreER) driven by the chick b-actin promoter/enhancer
coupled to the cytomegalovirus immediate-early enhancer
(CagCreER). The chondrocytes from CagCreER;b-cateninﬂ/ﬂ
and b-cateninﬂ/ﬂ mouse cartilage were treated with 1 mmol/L
4-hydroxytamoxifen for 2 days; immunoblot analysis con-
ﬁrmed that the former contained no detectable b-catenin,
whereas the control cells did (Figure 6D). Both populations
were transplanted subcutaneously into athymic mice. The
control chondrocyte transplants were completely replaced by
bone and fatty marrow by 4 weeks (Figure 6A), whereas the
tissue formed by b-catenin-deﬁcient chondrocytes showed
resistance to bone replacement and persisted as a cartilaginous
mass (Figure 6B) comprising heterogeneous cells (Figure 6C).
To further examine the normal roles of b-catenin
signaling on cell apoptosis, we treated normal chondrocytes
with 6BIO, a stimulator of the Wnt/b-catenin signaling
pathway. Treatment with 6BIO changed the cell mor-
phology, and many cells were shrunken and had irregular
cell membranes (Figure 7B). TUNEL staining revealed thattransplanted b-cateninedeﬁcient chondrocytes to bone replacement.
ere isolated from b-cateninﬂ/ﬂ mice (A) and CagCreER;b-cateninﬂ/ﬂ
bconﬂuence and then treated with 1 mmol/L 4-hydroxytamoxifen for
g in 4-hydroxytamoxifen-free medium for 2 additional days. Cells were
usly transplanted in athymic mice (see Materials and Methods). The
ere harvested 4 weeks after cell transplantation and subjected to
Enlargement of boxed area shown in B. D: Immunoblot analysis
;b-cateninﬂ/ﬂ mice contained no detectable b-catenin while the control
d b-catenin.
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Cantley et althe 6BIO-treated cultures contained many apoptotic cells
(Figure 7E). A cell viability assay showed that 6BIO had
impaired cell survival in a dose-dependent manner
(Figure 7G), whereas treatment with a control inactive
reagent, Me-7BIO, did not induce any appreciable changes
in the previously described parameters (Figure 7, C, F, and
G), as also seen in the cultures receiving the vehicle
(dimethyl sulfoxide) (Figure 7, A, D, and G). Furthermore,
6BIO treatment enhanced the apoptotic effects of high doses
of calcium and phosphate ions known to cause apoptosis in
growth plate chondrocytes33,34 (Figure 7G).
b-Catenin in Human Osteochondromas and Growth
Plates
Osteochondromas typically contain a cartilage cap and
underlying bone. Surgically retrieved cartilage caps fromFigure 7 Stimulation of cell apoptosis and cell death in chondrocytes by 6BIO
were treated with 2 mg/mL 6BIO (B), 2 mg/mL Me-7BIO (C), or vehicle (A) dim
photographic images were taken (AeC). G: Cells were treated with 6BIO, Me-7BI
NaH2PO4 (Ca
2þ/Pi) for 24 hours and were subjected to a cell viability assay. *P
924HME patients and rib growth plate sections from fetal
autopsies were subjected to immunohistochemical analysis
of b-catenin. We divided the cartilage caps into two regions
(Supplemental Figure S3A): a surface region generally
consisting of single cells (Figure 8I) and a deeper part
located closer to the bone consisting of relatively large cells
(Figure 8J). We only observed relatively weak b-catenin
staining in some of the solitary cells and large cells
(Figure 8, A, B, E, and F). The resting zone and hypertro-
phic zone in the control growth plates were separately
inspected (Supplemental Figure S3B). The degree of
b-catenin staining was very low in the resting zone
(Figure 8, C and G), but fairly high in the hypertrophic zone
(Figure 8, D and H). The number of b-cateninepositive
cells in the cartilage caps was comparable to that seen in
the resting zone but was much lower than that in the
hypertrophic zone (Figure 8M), suggesting that cartilagetreatment. AeF: Epiphyseal chondrocytes isolated from B6129SF2/J mice
ethyl sulfoxide for 24 hours and subjected to TUNEL staining (DeF) after
O, or vehicle in the presence or absence of 3 mmol/L CaCl2 and 6 mmol/L
< 0.05.
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Figure 8 Immunolocalization of b-catenin in ostechondromas and rib growth plates. AeL: Sections of osteochondromas from HME patients (A, B, E, F, I, and
J) and rib growth plate obtained from autopsy (C, D, G, H, K, and L) were subjected to immunoﬂuorescence staining for b-catenin. Cartilage caps of osteo-
chondromas were divided into two parts: a region composing of solitary and relatively small cells (Solitary), and a region adjacent to the bone and composed of
relatively large cells (Large). Resting zone (Resting) and hypertrophic zone (Hypertrophy) of growth plates were separately inspected. AeD: b-catenin staining;
(EeH) merged images of b-catenin staining (red) and DAPI nuclear staining (blue); (IeL) phase contrast images (AeD), respectively. M: Ratios of b-catenin
positive cells were evaluated as previously described (see Materials and Methods). *P < 0.05.
Loss of b-Catenin and Chondroma Formationcaps in osteochondromas in HME patients have lower
b-catenin signaling activity than that present in normal
growth plates.
Discussion
Mechanisms of Ectopic Chondroma-Like Mass
Formation in the b-Catenin Deﬁcient Mice
We demonstrate here that postnatal conditional ablation of b-
catenin induces formationof periosteal cartilagemasses inmice.
Our data relate well with those in previous studies showing that
loss of b-catenin can induce ectopic cartilage formation during
embryogenesis.26,27 These reports have also indicated that b-
catenin signaling is required for osteoblast differentiation of
mesenchymal cells and that the absence of b-catenin induces
mesenchymal cell differentiation into chondrocytes. In ourThe American Journal of Pathology - ajp.amjpathol.orgmouse models, Cre-recombinase activity was largely limited to
cartilage and was essentially undetectable in noncartilaginous
tissues, including perichondrium and periosteum. The data
suggest that ectopic cartilage originates via abnormal expansion
of the growth plate into the lateral site of perichondrium and is
eventually embedded within the periosteum with time. It is
therefore likely that ectopic cartilage formation is largely
induced by abnormal behavior and function of growth plate
chondrocytes in our models. However, we cannot exclude
the possibility that neodifferentiation of perichondrium or
periosteum-associated skeletal progenitor cells into chon-
drocytes may also contribute to ectopic cartilage formation.
Our data offers insights into possiblemechanisms bywhich
cartilage outgrowths form. One possibility is suggested by the
apparent differences in chondrocyte proliferation in the
central versus peripheral portions of mutant growth plates.
The rates appear to be higher in the lateral part than in the925
Cantley et alcenter growth plate revealed by PCNA staining. This imbal-
ance of cell proliferating activity could derange coordinated
longitudinal expansion of the growth plate and lead to lateral
overgrowth. In addition, the perichondrium ﬂanking the
outgrowing growth plate in the tamoxifen-injected mutant
mice appears thinner than that in the control growth plate.
Such alteration could decrease the mechanical strength of the
perichondrium, resulting in deformation and outgrowth of the
growth plate. The outgrowing growth plate initially contained
hypertrophic cells positive for collagen 10 and apoptotic cells
at the base. These cells had not activated Cre-recombinase, as
determined by b-galactosidase activity in Col2CreER;b-cat-
eninﬂ/ﬂmice inRosa-LacZ background. In contrast, the ectopic
cartilaginousmasses embedded in the periosteumat later stages
did not contain collagen 10 positive cells and apoptotic cells,
and most of the cells were b-galactosidase-positive and likely
b-catenin-deﬁcient. Furthermore, transplants of b-catenin-
deﬁcient chondrocytes into athymic mice were not replaced
by bone and remained cartilaginous for long periods of time.
Wnt/b-catenin signaling has been demonstrated to stimulate
cell proliferation and survival in various types of cells,
especially in cancer cells.35,36 However, activation of this
signaling stimulates apoptosis, as well as proliferation in
intestinal epithelial cells in vivo37 and also controls frequency
of apoptosis in hematopoietic stem/progenitor cells through
suppressing Bcl2 expression.38 Furthermore, overexpression
of b-catenin causes cell death independently of its trans-
activation function.39 Thusb-catenin could regulate apoptosis
in chondrocytes through multiple mechanisms and contexts.
Taken together, our data indicate that hypertrophic cells
within the outgrowing lesion did not undergo ablation of the
b-catenin gene, but were brought along by the b-catenin-
deﬁcient chondrocytes during deformation of the growth plate,
proceeded toward the endochondral bone formation process,
and were replaced by bone while the b-catenin-deﬁcient cells
remained as cartilaginous masses within the periosteum. Thus,
the process of ectopic chondroma-like mass formation in our
mousemodel canbedivided into twostages.Lossofb-catenin in
the growth platewould initially induce a deformity of the growth
plate resulting in lateral outgrowth of the growth plate itself.
Subsequently, the b-catenin deﬁcient chondrocytes would resist
hypertrophy and apoptosis and would give rise to long-lasting
ectopic cartilaginous masses persisting within the periosteum.
b-Catenin Signaling in Chondroma Formation
Recent studies have suggested that dysregulation of hedgehog
andﬁbroblast growth factor signaling results in osteochondroma
formation under conditions of deﬁciency ofEXT expression and
heparan sulfate production in HME patients.5,13 In the present
study, we observed similarities in the formation of ectopic
chondroma-likemasses in between ourb-catenin-deﬁcientmice
and the Extmutant mice previously reported to represent HME
osteochondromamodels.17e19 The topography and histology of
ectopic cartilaginousmasses forming inourmousemodels show
features similar to those in Ext mutants17e19 in that they both926form adjacent to the growth plate in ribs, distal tibiae, and
proximal femurs, and they exhibit growth-plate like structures,
and persist in the periosteum over time. Similar outgrowths of
the growth plate were observed in two different types of mutant
mice.18,19However, thedeﬁciencyofb-catenin resulted inmore
severe skeletal deformity as compared to those in Extmutants,
indicating that b-catenin-deﬁcient mice may have additional
pathological complications. We also demonstrate here that the
cartilage caps present in HME patient osteochondromas con-
tained a much lower number of b-catenin-positive cells as
compared to hypertrophic chondrocytes of the normal growth
plate. These ﬁndings suggest that loss or decrease in b-catenin
signaling could be a novel pathway involved in the patho-
genesis of osteochondroma formation in HME. Genetic and
molecular interactions between the Wnt signaling pathway
and heparan sulfate proteoglycans have been demonstrated in
Drosophila and vertebrates.40e44 Furthermore, previous
studies have indicated that heparan sulfate proteoglycans
stabilize Wnt proteins and modulate Wnt signaling activities
negatively or positively.41,43,45e47 Our in vivo and in vitro
results are consistent with these reports. Thus, a deﬁciency
in heparan sulfate may decrease Wnt/b-catenin signaling,
which in turn could contribute to long-term persistence of
cartilage caps in osteochondromas.
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